The company successfully acquired a promising therapeutic asset (AT177) with strong clinical potential, secured substantial financing ($64M) from reputable investors, and appointed an experienced board member. The acquisition positions the company to advance through key clinical milestones with adequate capitalization.
Articles that tag ADIL but are mainly about other companies.
Leading developer of AD04, a genetically guided therapy in Phase III trials with companion diagnostic test. Expected to capture largest market share by 2036. Recent partnership agreement with Molteni Farmaceutici for European commercialization and patent protection through 2045.
Golidocitinib, the first and only selective JAK1 inhibitor for R/R PTCL, has published Phase I and pivotal trial data in peer-reviewed journals; presented new data at ASH annual meeting across multiple PTCL subtypes.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
